Key Drivers
- Strong liquidity
- Low leverage
- Persistent losses
AIAI Summary
Azenta's investment case has shifted from growth-at-scale to a turnaround hinged on margin recovery—investors should monitor ABS-driven ~300bp EBITDA improvement, remediation cost transparency, North American lab utilization, and scalable free-cash-flow that justifies the $250M buyback because hitting those specific operational and cash-flow proof points would trigger a re‑rating while misses (continued negative EPS/goodwill risk or buybacks draining flexibility) would drive downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Low leverage
- •Persistent losses
Azenta has healthy liquidity and very low leverage but persistent net losses and negative returns despite improving quarterly EBITDA and cash flow, making it operationally stabilizing yet still a profitability risk.
Price Behavior
Key Price Behavior Insights:
- •Price below SMA
- •Elevated RSI
- •Support tested
AZTA is short-term bearish—closing $20.19 below its last month SMA (~$24.25) with RSI ~77, key support $20.0–$21.0 (tested) and a break below would confirm further downside while a sustained move above $24.0–$25.0 is needed to shift the trend.
Sharp decline from late
Sentiment & News
Key News Insights:
- •UK expansion
- •Investor engagement
- •Mixed sentiment
Azenta completed the UK Biocentre acquisition and stepped up investor engagement in early March, signaling inorganic growth while analysts maintain a Hold consensus with a $41.33 midpoint target.
The UK deal boosts Azenta's sample management and throughput capacity and supports long-term growth, but the Hold consensus and tempered analyst views suggest limited near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings